Investor Relations

A man with his arms crossed

NASDAQ: PNT

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT aims to transform precision oncology by combining a portfolio of targeted radioligand assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for medical isotopes including actinium-225 and lutetium-177. POINT’s active clinical trials include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program targeting fibroblast activation protein-α (FAP-α), and SPLASH, the phase 3 trial for PNT2002 for people with metastatic castration resistant prostate cancer (mCRPC) after second-line hormonal treatment.

https://vimeo.com/640342249
false
false
true
Play
Video
Press Release
18 Sep
2023

POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands

Enables the efficient expansion of surface targets for radioisotope delivery

Press Release
14 Aug
2023

POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023. Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024. Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212.